China SXT Pharmaceuticals, Inc. — Form 20-F Summary
Reporting period: The provided filing is an annual report for the fiscal year ended March 31, 2020, not a standalone 2019 fourth-quarter filing. Financial statements are prepared under U.S. GAAP and presented in U.S. dollars.
Business context
China SXT is a British Virgin Islands holding company whose operations are conducted primarily in China through subsidiaries and a variable interest entity, Taizhou Suxuantang. The company researches, manufactures, markets and sells traditional Chinese medicine pieces, including Advanced, Fine and Regular TCMP products, as well as TCM Homologous Supplements.
- Revenue mix in fiscal 2020: Advanced TCMP 30.6%, Fine TCMP 20.0%, Regular TCMP 44.2%; TCMHS products contributed the remainder.
- Substantially all operations, assets and revenue are located in China, and the company relies on contractual VIE arrangements rather than direct equity ownership of its principal operating entity.
- The company had 34,667,707 ordinary shares outstanding as of March 31, 2020.
Key financial metrics
| Metric | Fiscal 2020 | Fiscal 2019 | Change |
|---|---|---|---|
| Revenue | $5.162 million | $7.012 million | Down 26% |
| Gross profit | $2.704 million | $4.612 million | Down 41% |
| Gross margin | 52.4% | 65.8% | Down 13.4 percentage points |
| Operating income (loss) | $(1.341) million | $1.769 million | Turned to loss |
| Net income (loss) | $(10.288) million | $1.539 million | Turned to loss |
| Basic and diluted EPS | $(0.416) | $0.075 | Declined |
| Net cash from operations | $0.934 million | $0.239 million | Improved by $0.695 million |
| Net cash used in investing | $(5.497) million | $(0.610) million | Greater use of cash |
| Net cash from financing | $3.024 million | $9.042 million | Down $6.018 million |
| Cash and cash equivalents | $7.287 million | $9.131 million | Down $1.844 million |
| Total current assets | $19.636 million | $15.588 million | Up $4.048 million |
| Total current liabilities | $12.264 million | $6.321 million | Up $5.943 million |
| Total liabilities | $12.301 million | $6.363 million | Up $5.938 million |
| Total shareholders’ equity | $9.401 million | $11.108 million | Down $1.706 million |
Liquidity was approximately $7.372 million of working capital at March 31, 2020. Short-term convertible notes had a net carrying value of $6.643 million, while principal outstanding was $6.828 million. Management stated that existing cash and anticipated operating cash flows were sufficient for at least the next 12 months, but also stated that additional capital raising would be needed in the near future.
Material changes versus the prior comparable period
- Revenue declined $1.850 million, primarily because Advanced TCMP sales fell 56% to $1.582 million. Regular TCMP sales fell 20% to $2.279 million.
- Fine TCMP revenue increased 97% to $1.034 million as management emphasized higher-margin products. Four TCMHS solid beverages launched in April 2019 and generated $267,472.
- Gross margin contracted substantially because of lower Advanced TCMP revenue, lower Regular TCMP margins, packaging changes and fixed production costs during COVID-19-related disruptions.
- General and administrative expense increased 99% to $2.462 million, including approximately $0.9 million of additional legal and investor-relations fees. Selling expense was broadly stable at $1.583 million.
- Other expense increased to $9.048 million, including $3.349 million of net interest expense and a $5.626 million loss on debt extinguishment related to the convertible-note forbearance transaction.
- Cash from operations increased despite the reported net loss, largely because of non-cash convertible-note accretion and extinguishment charges and changes in working-capital liabilities.
- Investing cash outflows increased primarily because of a $3.590 million investment deposit, a $1.500 million loan receivable and capital expenditures.
- The company issued 11,961,006 ordinary shares for partial settlement of convertible-note principal and interest, increasing dilution. Subsequent to year-end, it reported issuing an additional 25,469,183 shares through July 30, 2020 for further note settlement.
Debt, contingencies and unusual items
- In May 2019, the company issued $15 million of senior convertible notes and warrants. The notes carried an 8% annual interest rate, increasing to 18% upon default, and had an initial conversion price of $8.38 per share.
- Investors issued default redemption notices in July 2019. In December 2019, the company entered into forbearance agreements requiring an aggregate redemption price of approximately $10.939 million plus an initial $1 million forbearance fee and other potential amounts.
- The company stated that failure to meet the forbearance obligations could trigger additional redemption demands, liquidated damages, share issuance, dilution and adverse liquidity effects. The Series A warrant exercise price was reduced from $8.38 to $2.50.
- The company had financial guarantees for related-party borrowings totaling approximately $0.918 million at March 31, 2020. Subsequent guarantees entered in April and May 2020 totaled approximately $0.890 million.
- The company committed $7 million to the Huangshan Panjie investment fund. It later agreed to withdraw the $3.5 million installment paid in June 2019, received $2.8 million in June 2020 and expected to collect the balance by October 2020.
- A $1.5 million loan to RH Holdings Management matured on May 31, 2020 and was not renewed; management expected full collection by October 2020.
- The company reported no material pending legal proceedings and no material off-balance-sheet arrangements, but it does not maintain product-liability, business-interruption or key-person insurance.
COVID-19, outlook and management commentary
COVID-19 caused temporary closures of offices and production facilities in Jiangsu from late January to mid-March 2020. Production resumed in mid-March and returned to normal levels in May 2020, but logistics, customer demand and collections were disrupted. The company estimated that April through June 2020 revenue could be approximately 26% below the comparable prior-year period. Management noted continued uncertainty regarding renewed outbreaks and the duration of business disruptions.
Management expects to expand its customer and distribution base, promote Advanced and Fine TCMP products, develop additional products and seek additional debt or equity financing. No formal long-term revenue or earnings guidance is provided in the filing.
The company’s auditor issued an unqualified opinion on the financial statements, but management concluded that disclosure controls and internal control over financial reporting were not effective as of March 31, 2020. Reported deficiencies included inadequate U.S. GAAP-capable bilingual accounting personnel and insufficient segregation of duties.
Principal investor risks
- Liquidity and refinancing risk from convertible-note obligations, potential cash redemptions, continued operating losses and dependence on additional financing.
- Significant dilution risk from note conversions, warrants and subsequent share issuances.
- COVID-19-related risks affecting production, logistics, demand, collections and suppliers.
- Dependence on a small customer base: two customers represented 20.23% and 15.00% of fiscal 2020 revenue.
- Regulatory and licensing risk, including renewal of the pharmaceutical manufacturing permit, which was scheduled to expire December 31, 2020, and continuing GMP and NMPA compliance.
- VIE structural risk because the company does not directly own its principal operating entity and relies on PRC contractual arrangements whose enforceability and regulatory treatment remain uncertain.
- PRC foreign-exchange, tax, capital-transfer and dividend-repatriation restrictions.
- Customer, raw-material, product-liability, intellectual-property and pricing risks in the traditional Chinese medicine market.
Facts investors should verify
- Current status, maturity, remaining principal, conversion activity and settlement terms of the convertible notes and warrants.
- Shares issued after March 31, 2020 and the resulting fully diluted share count.
- Whether the company successfully renewed its pharmaceutical manufacturing permit and maintained GMP compliance.
- Collection of the remaining Huangshan Panjie investment proceeds and the RH Holdings loan.
- Actual revenue recovery after the COVID-19 disruption and whether Advanced TCMP demand has stabilized.
- Remediation of the disclosed material weaknesses and effectiveness of internal controls in subsequent filings.
- Outstanding related-party guarantees and the ability of the guaranteed borrowers to repay their bank debt.
- Customer concentration, accounts-receivable collectability and the company’s access to additional financing.